Status:

ACTIVE_NOT_RECRUITING

A Study of REC-4881 in Participants with Cancers Which Have an AXIN1 or APC Mutation

Lead Sponsor:

Recursion Pharmaceuticals Inc.

Conditions:

AXIN1 Gene Mutation

APC Gene Mutation

Eligibility:

All Genders

55+ years

Phase:

PHASE2

Brief Summary

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advance...

Detailed Description

Approximately 60 individuals will be enrolled in this open-label Phase 2 study, allocated 1:1 between the 2 cohorts - AXIN1 mutation or APC mutation. The purpose of the study is to investigate the saf...

Eligibility Criteria

Inclusion

  • 55 years of age or older with histologically-confirmed unresectable, locally advanced, or metastatic solid tumor with AXIN1 or APC mutation. If a participant has colorectal cancer, then they must be RAS / RAF wild type to enroll into the APC mutant cohort
  • Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment, or in the opinion of the Investigator have been considered ineligible for standard therapy
  • Measurable disease at baseline per RECIST 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Exclusion

  • Received treatment with another mitogen-activated protein kinase (MEK) inhibitor within two months of first dose of REC-4881
  • Left ventricular ejection fraction (LVEF) \<50% as measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan

Key Trial Info

Start Date :

January 15 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2027

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06005974

Start Date

January 15 2024

End Date

January 1 2027

Last Update

November 29 2024

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Sharp Memorial Hospital

San Diego, California, United States, 92123

2

Sansum Clinic

Santa Barbara, California, United States, 93105

3

Rocky Mountain Cancer Centers

Denver, Colorado, United States, 80218

4

Eastern Connecticut Hematology & Oncology Associates

Norwich, Connecticut, United States, 06360